JPWO2022047237A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022047237A5
JPWO2022047237A5 JP2023514105A JP2023514105A JPWO2022047237A5 JP WO2022047237 A5 JPWO2022047237 A5 JP WO2022047237A5 JP 2023514105 A JP2023514105 A JP 2023514105A JP 2023514105 A JP2023514105 A JP 2023514105A JP WO2022047237 A5 JPWO2022047237 A5 JP WO2022047237A5
Authority
JP
Japan
Prior art keywords
cell
dna template
size
primary immune
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023514105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543137A5 (https=
JP2023543137A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048066 external-priority patent/WO2022047237A1/en
Publication of JP2023543137A publication Critical patent/JP2023543137A/ja
Publication of JP2023543137A5 publication Critical patent/JP2023543137A5/ja
Publication of JPWO2022047237A5 publication Critical patent/JPWO2022047237A5/ja
Withdrawn legal-status Critical Current

Links

JP2023514105A 2020-08-28 2021-08-27 プライミング受容体で操作された免疫細胞 Withdrawn JP2023543137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072080P 2020-08-28 2020-08-28
US63/072,080 2020-08-28
PCT/US2021/048066 WO2022047237A1 (en) 2020-08-28 2021-08-27 Engineered immune cells with priming receptors

Publications (3)

Publication Number Publication Date
JP2023543137A JP2023543137A (ja) 2023-10-13
JP2023543137A5 JP2023543137A5 (https=) 2024-09-03
JPWO2022047237A5 true JPWO2022047237A5 (https=) 2024-09-03

Family

ID=80352430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514105A Withdrawn JP2023543137A (ja) 2020-08-28 2021-08-27 プライミング受容体で操作された免疫細胞

Country Status (10)

Country Link
US (1) US20230340409A1 (https=)
EP (1) EP4204575A4 (https=)
JP (1) JP2023543137A (https=)
KR (1) KR20230083275A (https=)
CN (1) CN116529364A (https=)
AU (1) AU2021334366A1 (https=)
CA (1) CA3191148A1 (https=)
IL (1) IL300994A (https=)
MX (1) MX2023002455A (https=)
WO (1) WO2022047237A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302315A (en) * 2020-10-26 2023-06-01 Arsenal Biosciences Inc Secure port sites
EP4496806A2 (en) * 2022-04-20 2025-01-29 Arsenal Biosciences, Inc. Cells comprising a suppressor of gene expression and/or a synthetic pathway activator and/or an inducible payload
AU2023272589A1 (en) * 2022-05-17 2025-01-09 Arsenal Biosciences, Inc. Systems of engineered receptors targeting psma and ca9
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
PE20252678A1 (es) * 2023-03-13 2025-11-24 Arsenal Biosciences Inc Activadores de vias sinteticas
CN121674486A (zh) * 2026-02-10 2026-03-17 潍坊吉涛医学科技有限公司 基于慢病毒载体的羊膜细胞永生化建系方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175636A2 (en) * 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
MX2020004541A (es) * 2017-10-30 2021-04-12 Pact Pharma Inc Edicion de genes de celulas primarias.
EP3796894A4 (en) * 2018-04-24 2022-05-04 Ligandal, Inc. METHODS AND COMPOSITIONS FOR GENOMIC EDITING
CN110184301B (zh) * 2018-04-28 2023-02-24 辉大(上海)生物科技有限公司 通过Tild-CRISPR实现高效精确的靶向整合
AU2020355025A1 (en) * 2019-09-23 2022-04-07 Regents Of The University Of Minnesota Genetically-edited immune cells and methods of therapy
IL302315A (en) * 2020-10-26 2023-06-01 Arsenal Biosciences Inc Secure port sites
JP2024512608A (ja) * 2021-03-24 2024-03-19 ジェネンテック, インコーポレイテッド Tリンパ球における効率的なtcr遺伝子編集
CA3227759A1 (en) * 2021-08-11 2023-02-16 Sebastien Levesque Mtor-targeted modification and uses thereof

Similar Documents

Publication Publication Date Title
US11931426B2 (en) Recombinogenic nucleic acid strands in situ
JP2024174943A5 (https=)
JP2023100828A5 (https=)
Redwood et al. Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception
JP2025063317A5 (https=)
JP2021522820A5 (https=)
CN114174325A (zh) 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
Santosuosso et al. Adenoviral vectors for mucosal vaccination against infectious diseases
JP2021500072A5 (https=)
CN103382468B (zh) 一种水稻基因组定点改造方法
JP2021500889A5 (https=)
JP2018534950A5 (https=)
JPWO2020163365A5 (https=)
US11998567B2 (en) Engineered chimeric guide RNA and uses thereof
JPWO2018232356A5 (https=)
WO2021082784A1 (zh) 一种基于腺病毒的基因编辑方法
AU2021300358A1 (en) Methods and compositions for editing the B2M locus in B cells
JPWO2022047237A5 (https=)
CN110499335B (zh) CRISPR/SauriCas9基因编辑系统及其应用
CN106282230B (zh) 定点突变ldlr基因的方法
CN110551762B (zh) CRISPR/ShaCas9基因编辑系统及其应用
Bertino et al. Vaccination with a piggyBac plasmid with transgene integration potential leads to sustained antigen expression and CD8+ T cell responses
CN106244556A (zh) 定点突变ApoE基因的方法
JPWO2022093863A5 (https=)
Epstein et al. 119. Engineering a self-inactivating CRISPR system for AAV vectors